

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Lloyd S. Gray et al.	Examiner:	Christopher Yaen
Serial No.:	10/589,216	Group Art Unit:	1642
Filed:	January 15, 2008	Docket:	1036.115US1
Customer No.:	21186	Confirmation No.:	5782
Title:	Inhibiting Cav3 Isoforms and the 25B Splice Varients for the Diagnosis and Treatment of Cancer		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached PTO 1449 Form be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the PTO 1449 Form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

The attached documents were discovered as a result of a Search Report in Applicants' corresponding foreign patent application. Enclosed for the Examiner's information is a copy of the cited documents and the Search Report.

Pursuant to 37 C.F.R. § 1.97(c)(1) and 37 C.F.R. § 1.97(e)(1), Applicants state that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Pursuant to 37 C.F.R. § 1.98(a)(2), copies of cited U.S. Patents and Published

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial Number:10/589,216

Filing Date: January 15, 2008

Title: Inhibiting Cav3 Isoforms and the 25B Splice Variants for the Diagnosis and Treatment of Cancer

Page 2

Dkt: 1036.115US1

Applications, and Non-Published Applications identifiable by USPTO Serial Number, are no longer required to be provided to the Office. Applicants acknowledge the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R § 1.98(a)(2).

The Examiner is invited to contact the undersigned at the telephone number indicated if there are any questions regarding this communication.

Respectfully submitted,

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6905

Date September 8, 2010

By

/ Monique M. Rerdok Shonka /

Monique M. Rerdok Shonka

Reg. No. 42,989

MMP:pjm

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 9th day of September, 2010.

Patrick McNally

Name

/ Patrick McNally /
Signature